Integrated CRISPR-based detection of HIV, tuberculosis, malaria, and resistance-associated variants
In the authors' words
HIV, tuberculosis (TB) and malaria are major infectious diseases that frequently co-circulate in high-burden settings, yet their diagnostic pathways remain largely disease-specific, complicating detection of coinfection and integration of antimicrobial-resistance testing. Here we developed HTM CARMEN, a highly multiplexed CRISPR-Cas13a molecular-testing framework that integrates detection of HIV-1, HIV-2, four Plasmodium species and Mycobacterium tuberculosis (Mtb) with detection of isoniazid-resistance-associated inhA and katG variants. We find that HTM CARMEN retained target selectivity and single-nucleotide discrimination across in vitro experiments and clinically relevant sample matrices, including whole blood, serum, sputum and dried blood spots. Across 20 contrived samples for each condition, the HTM panel supported detection of low-abundance targets across multiple matrices and frequently detected greater number of low-input samples as positive than qPCR under the conditions tested. In contrived P. falciparum/HIV-1 and Mtb/HIV-1 coinfections, both pathogens were simultaneously detected across a range of relative target concentrations. Using confirmed-positive clinical samples, HTM CARMEN achieved positive percent agreement of 95% for malaria (19/20), 95% for HIV-1 (19/20) and 100% for Mtb (30/30), with 100% negative percent agreement for each target in the confirmed-negative samples. Both HIV-1 and Mtb were additionally detected in all nine confirmed-positive HIV-TB coinfection specimens. These findings establish the feasibility of integrating pathogen detection, species differentiation, resistance-associated variant interrogation and coinfection detection within a programmable molecular-testing platform, providing a framework for high-throughput integrated testing in co-endemic settings.
In plain words AI summary
The authors developed HTM CARMEN, a CRISPR-based test that detects HIV, tuberculosis, malaria, and drug-resistance variants in one platform. The test correctly identified 95% of malaria and HIV-1 samples, and 100% of tuberculosis samples in confirmed-positive clinical specimens. It detected both pathogens in all nine samples with confirmed HIV-tuberculosis coinfection. The test also found both malaria and HIV, or tuberculosis and HIV, in artificial mixed infections at varying concentrations. These results show that combining pathogen detection, species identification, resistance testing, and coinfection detection in one system is possible.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.
Appeared: Wednesday, September 30. medRxiv. Preprint, not yet peer-reviewed.